American Journal of Cardiology
Volume 97, Issue 8, Supplement 1 , Pages S77-S81, 17 April 2006

An Assessment of Statin Safety by Hepatologists

  • David E. Cohen, MD, PhD

      Affiliations

    • Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School and Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Boston, Massachusetts, USA
    • Corresponding Author InformationAddress for reprints: David E. Cohen, MD, PhD, Division of Gastroenterology, Brigham and Women’s Hospital, Thorn 1405, 75 Francis Street, Boston, Massachusetts 02115.
  • ,
  • Frank A. Anania, MD

      Affiliations

    • Emory University School of Medicine, Atlanta, Georgia, USA
  • ,
  • Naga Chalasani, MD

      Affiliations

    • Indiana University School of Medicine, Indianapolis, Indiana, USA.

published online 06 February 2006.

The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association’s (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-9149(05)02147-8

doi:10.1016/j.amjcard.2005.12.014

American Journal of Cardiology
Volume 97, Issue 8, Supplement 1 , Pages S77-S81, 17 April 2006